Aiko Watanabe

Mrs. Aiko Watanabe

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Veterinary Medical Science
Verified
Journal Article
Open access
AWAiko Watanabe
Aiko Watanabe
HMHironobu Murakami
Hironobu Murakami
SKSeiichi Kakinuma
Seiichi Kakinuma
KMKoki Murao
Koki Murao
KOKaori Ohmae
Kaori Ohmae
KKKazuhiro Kawai
Kazuhiro Kawai
The purpose of this study was to clarify the effect of Bovine leukemia virus (BLV) infection on natural immunity in the bovine mammary gland and on the severity of clinical mastitis. We classified milk samples from clinical mastitic cows into BLV-positive (n=76) and BLV-negative (n=12). BLV-positive cows were further divided into cows with High BLV proviral load (H-PVL) (n=23) and Low BLV proviral load (L-PVL) (n=53). Severity of clinical mastitis was classified as MILD, MODERATE, or SEVERE. Multiple logistic regression analysis was performed on the host factors and environmental factors with severity of clinical mastitis as the objective variable. BLV proviral load (PVL) and season at onset of mastitis showed significant correlation with the severity of clinical mastitis. Binary logistic regression analysis was performed on natural immunity factors lactoferrin and lingual antimicrobial peptide (LAP) concentration in milk, with PVL as the objective variable. Of these natural immunity factors, LAP concentration in milk showed significant correlation with PVL. The results of the present study suggested that PVL and season are associated with severity of clinical mastitis, and that the immune function in the mammary gland is decreased in cows with H-PVL compared to that in cows with L-PVL.

1 March 2024 in American Journal of Veterinary Research
Verified
Journal Article
Open access
PDF file
AWAiko Watanabe
Aiko Watanabe
HMHironobu Murakami
Hironobu Murakami
SKSeiichi Kakinuma
Seiichi Kakinuma
KMKoki Murao
Koki Murao
KOKaori Oomae
Kaori Oomae
KKKazuhiro Kawai
Kazuhiro Kawai
OBJECTIVE: To establish a threshold value of bovine leukemia virus (BLV) proviral load (PVL) to identify increased risk of severe clinical mastitis, and to examine the prognosis and economic loss of clinical mastitis based on the newly established PVL cut-off value. ANIMALS: 97 lactating Holstein cows with clinical mastitis. METHODS: Blood and milk samples were collected aseptically from each cow. Youden index was used for receiver-operating characteristic curve analysis with the severity rate of clinical mastitis as the dependent variable and PVL as an independent variable. PVL cut-off value was used as a criterion to compare the severity rate of clinical mastitis, percentage of cows with and without systemic treatments, number of treatments, cost of treatment, and prognosis. RESULTS: PVL cut-off value was 17.8 copies/10 ng DNA for the dependent variable MILD vs SEVERE. The severity rate of clinical mastitis, percentage of cows given systemic treatments, and technical fees for medical treatment were significantly higher in the group above the PVL cut-off value than in the group below the PVL cut-off value and the negative group. Number of treatments was significantly higher in the group above the cut-off value than in the group below the cut-off value. There was no significant difference in prognosis after mastitis among the 3 groups. CLINICAL RELEVANCE: These results suggested that PVL cut-off value of 17.8 copies/10 ng DNA was a useful threshold for increased economic losses in BLV-infected cows; it may also serve as a new standard value for the detection and culling of BLV-infected cows in Japan.

21 July 2025 in Animals
Verified
Journal Article
Open access
PDF file
AWAiko Watanabe
Aiko Watanabe
YMYosuke Maeda
Yosuke Maeda
HMHironobu Murakami
Hironobu Murakami
SMShiro Miyoshi
Shiro Miyoshi
MMMichisaburo Miura
Michisaburo Miura
KKKazuhiro Kawai
Kazuhiro Kawai
Subclinical mastitis causes economic losses due to reduced milk yield and elevated somatic cell counts (SCCs), despite no visible clinical signs. A higher incidence of subclinical mastitis has been reported in cattle infected with bovine leukemia virus (BLV). Levamisole (LMS), known for its immunomodulatory properties, has been suggested as a potential alternative to antibiotics for mastitis treatment; however, its efficacy in BLV-infected cows, particularly in relation to proviral load (PVL), remains unclear. This study aimed to evaluate the therapeutic effect of LMS on subclinical mastitis and its impact on milk immune responses by classifying BLV-infected cows based on PVL. A total of 42 dairy cows with subclinical mastitis (48 quarters) were grouped as BLV-negative, low-PVL, or high-PVL using a PVL cut-off value of 17.8 copies/10 ng DNA, and were administered LMS orally. Changes in viable bacterial counts, SCCs, and milk leukocyte populations were compared. LMS administration significantly reduced the SCC and milk macrophage numbers, especially in BLV-negative and low-PVL cows. These results suggest that LMS may improve subclinical mastitis in certain BLV-infected cows and that PVL may serve as a useful indicator for treatment responsiveness. However, the limited effect in high-PVL cows and the small sample size have limitations, warranting further investigation.